Tags

Type your tag names separated by a space and hit enter

Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
Clin Lung Cancer. 2010 Mar 01; 11(2):114-9.CL

Abstract

BACKGROUND

The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC.

PATIENTS AND METHODS

A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative real-time reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected.

RESULTS

Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor.

CONCLUSION

In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted.

Authors+Show Affiliations

Department of General, Visceral and Cancer Surgery, University of Cologne, Germany. pgrimminger@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

20199977

Citation

Grimminger, Peter P., et al. "Ornithine Decarboxylase mRNA Expression in Curatively Resected Non-small-cell Lung Cancer." Clinical Lung Cancer, vol. 11, no. 2, 2010, pp. 114-9.
Grimminger PP, Schneider PM, Metzger R, et al. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer. Clin Lung Cancer. 2010;11(2):114-9.
Grimminger, P. P., Schneider, P. M., Metzger, R., Vallböhmer, D., Danenberg, K. D., Danenberg, P. V., Hölscher, A. H., & Brabender, J. (2010). Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer. Clinical Lung Cancer, 11(2), 114-9. https://doi.org/10.3816/CLC.2010.n.015
Grimminger PP, et al. Ornithine Decarboxylase mRNA Expression in Curatively Resected Non-small-cell Lung Cancer. Clin Lung Cancer. 2010 Mar 1;11(2):114-9. PubMed PMID: 20199977.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer. AU - Grimminger,Peter P, AU - Schneider,Paul M, AU - Metzger,Ralf, AU - Vallböhmer,Daniel, AU - Danenberg,Kathleen D, AU - Danenberg,Peter V, AU - Hölscher,Arnulf H, AU - Brabender,Jan, PY - 2010/3/5/entrez PY - 2010/3/5/pubmed PY - 2010/5/26/medline SP - 114 EP - 9 JF - Clinical lung cancer JO - Clin Lung Cancer VL - 11 IS - 2 N2 - BACKGROUND: The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC. PATIENTS AND METHODS: A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative real-time reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected. RESULTS: Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor. CONCLUSION: In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted. SN - 1938-0690 UR - https://www.unboundmedicine.com/medline/citation/20199977/Ornithine_decarboxylase_mRNA_expression_in_curatively_resected_non_small_cell_lung_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1525-7304(11)70007-9 DB - PRIME DP - Unbound Medicine ER -